64,364 Shares in Caribou Biosciences, Inc. (NASDAQ:CRBU) Acquired by Sei Investments Co.

Sei Investments Co. purchased a new stake in shares of Caribou Biosciences, Inc. (NASDAQ:CRBU) in the fourth quarter, according to its most recent 13F filing with the SEC. The fund purchased 64,364 shares of the company’s stock, valued at approximately $102,000.

A number of other institutional investors and hedge funds also recently made changes to their positions in CRBU. US Bancorp DE grew its stake in Caribou Biosciences by 3,524.2% in the 4th quarter. US Bancorp DE now owns 27,218 shares of the company’s stock worth $43,000 after buying an additional 26,467 shares in the last quarter. Thrive Wealth Management LLC bought a new position in Caribou Biosciences in the fourth quarter valued at $51,000. Intech Investment Management LLC lifted its stake in Caribou Biosciences by 69.4% during the fourth quarter. Intech Investment Management LLC now owns 37,478 shares of the company’s stock worth $60,000 after purchasing an additional 15,352 shares during the last quarter. Barclays PLC increased its position in shares of Caribou Biosciences by 122.4% during the 3rd quarter. Barclays PLC now owns 129,839 shares of the company’s stock valued at $255,000 after purchasing an additional 71,463 shares during the last quarter. Finally, American Century Companies Inc. lifted its position in Caribou Biosciences by 9.2% in the 4th quarter. American Century Companies Inc. now owns 159,822 shares of the company’s stock worth $254,000 after buying an additional 13,421 shares during the last quarter. Hedge funds and other institutional investors own 77.51% of the company’s stock.

Caribou Biosciences Trading Up 1.7 %

Shares of CRBU stock opened at $0.87 on Friday. The company’s fifty day moving average price is $1.09 and its 200-day moving average price is $1.61. The stock has a market cap of $81.31 million, a PE ratio of -0.53 and a beta of 2.36. Caribou Biosciences, Inc. has a 12 month low of $0.66 and a 12 month high of $4.39.

Caribou Biosciences (NASDAQ:CRBU) last posted its quarterly earnings results on Monday, March 10th. The company reported ($0.39) earnings per share for the quarter, topping the consensus estimate of ($0.40) by $0.01. Caribou Biosciences had a negative return on equity of 45.46% and a negative net margin of 1,290.81%. The company had revenue of $2.08 million for the quarter, compared to the consensus estimate of $2.11 million. On average, sell-side analysts forecast that Caribou Biosciences, Inc. will post -1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

CRBU has been the subject of a number of recent research reports. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Caribou Biosciences in a report on Wednesday, March 19th. Bank of America cut their price target on shares of Caribou Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus price target of $10.33.

Caribou Biosciences Company Profile

Caribou Biosciences, Inc, a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma.